AstraZeneca FY26 H1 reported EPS rises 4% to $3.60; revenue climbs 9% to $30.67 billion - AZN News | RalliesAstraZeneca FY26 H1 reported EPS rises 4% to $3.60; revenue climbs 9% to $30.67 billion
A
AZN• AstraZeneca reports higher first-half revenue and earnings
- AstraZeneca reported H1 2026 revenue of USD 30.67 billion, up 9% from a year earlier.
- Reported EPS rose 4% to USD 3.60, while core EPS climbed 12% to USD 5.21.
- Q2 revenue increased 6% to USD 15.38 billion; reported EPS rose 2% to USD 1.61.
- H1 product sales grew 8% to USD 28.9 billion, while alliance revenue jumped 31% to USD 1.7 billion.
- Management said it remains on track for its USD 80 billion total revenue ambition for 2030, despite the CARDIO-TTRansform outcome.
•
